Answers are grounded in this paper and cite their sources.
Observational pilot study shows a new protein substitute improves adherence in children with PKU, suggesting a beneficial dietary option.
Background/Objectives: In phenylketonuria (PKU), adherence to protein substitute (PS) is frequently suboptimal due to poor palatability, high volume, and sensory fatigue. A novel phenylalanine (Phe)-free L-amino acid microtablet PS has been developed to address these barriers. The microtablets incorporate a cellulose-based taste-masking coating and a sodium-alginate inner matrix intended to enable controlled amino acid release over approximately three hours. This study evaluated their short-term tolerability, acceptability, and adherence in children with PKU, with extended follow-up in a subgroup. Methods: A 7-day observational study was conducted in participants with PKU aged ≥3 years on a low-Phe diet in a single centre. The test product provided protein equivalent (PE) 54 g/100 g. Participants replaced at least one daily dose of their usual PS with the test product, providing 10 g or 20 g/day PE, with one child receiving 80 g/day. Daily gastrointestinal (GI) symptoms, PS intake, and adherence were recorded. Acceptability was assessed using structured ratings of palatability, ease of use, and overall preference. Longer-term tolerability and acceptability were then assessed in four adolescents who elected to continue the test product for an additional 28 days. Results: Ten participants completed the 7-day study. Adherence to the test product was high (80%), exceeding adherence to participants’ usual PS (70%). At baseline, nine participants reported none/mild GI symptoms, most commonly flatulence. One participant reported moderate/severe symptoms including constipation, flatulence, diarrhoea, bloating, burping, and abdominal discomfort. By day 7, all participants reported no or mild symptoms, with complete resolution in the child with moderate/severe baseline symptoms. Acceptability ratings were comparable between the test product and usual PS, and nine children (90%) reported no difficulty taking the test product. During the 28-day extension, adherence remained high, GI tolerance was maintained, and improved preference was noted, particularly due to reduced aftertaste. Conclusions: This novel slow-release PS microtablet was well tolerated, acceptable, and associated with high adherence. Its taste-masked, low-volume format offered practical advantages that may support sustained dietary adherence. Longer-term controlled studies are necessary to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Tosi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: